220 results on '"Kang, Yubin"'
Search Results
2. Strain-induced modulation of the band structure of GaAs/GaSb/GaAs core-dual-shell nanowires
3. Effect of InAs insertion layer on the structural and optical property improvement of InGaAs/InAlAs multiple quantum wells
4. Design and optimization of the performance of self-powered Sb2S3 photodetector by SCAPS-1D simulation and potential application in imaging
5. Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma
6. Domain-specific valuation of university technologies using bibliometrics, Jonckheere–Terpstra tests, and data envelopment analysis
7. Influence of atom segregation on the structure and luminescence of InGaAsSb/AlGaAsSb multiple quantum wells
8. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
9. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
10. Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor
11. Dual functions of microRNA-17 in maintaining cartilage homeostasis and protection against osteoarthritis
12. Effect of Annealing Voltage in Joule Heating on Microstructure and Physical Properties of 16-Strand Compressed Conductor
13. Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation
14. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease
15. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy
16. Combination Therapy Shows Synergistic Effect in Myeloma Treatment
17. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
18. Characterization of stainless steel surface processed using electrolytic oxidation and titanium complex ion solution
19. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma
20. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
21. Bulk Defect Passivation for Full‐Inorganic Sb2S3 Solar Cells by Sulfur‐Atmosphere Recrystallization Process.
22. Induction of Hyporesponsiveness to Intact Foreign Protein via Retroviral-Mediated Gene Expression: The IgG Scaffold Is Important for Induction and Maintenance of Immune Hyporesponsiveness
23. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
24. RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect.
25. The Self-Catalyzed Growth of GaAsSb Nanowires on a Si (111) Substrate Using Molecular-Beam Epitaxy.
26. Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification
27. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
28. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
29. Insulin-Like Growth Factor 1 Mitigates Hematopoietic Toxicity After Lethal Total Body Irradiation
30. Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma.
31. Controlling the morphology and wavelength of self-assembled coaxial GaAs/Ga(As)Sb/GaAs single quantum-well nanowires.
32. Acceptance and Commitment Therapy May Improve Physical Function after Allogeneic Hematopoietic Stem Cell Transplant
33. Incidence and Characteristics of Respiratory Viral Infections after CAR T-Cell Therapy
34. Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma.
35. The Effect of Bi and Zn Additives on Sn-Ag-Cu Lead-Free Solder Alloys for Ag Reduction.
36. Emerging Evidence of the Significance of Thioredoxin-1 in Hematopoietic Stem Cell Aging.
37. Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor
38. P-396 Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma
39. CHAPTER SEVEN: Thioredoxin and Hematologic Malignancies
40. A thermo-sensitive and injectable hydrogel derived from a decellularized amniotic membrane to prevent intrauterine adhesion by accelerating endometrium regeneration.
41. A New Reality for Multiple Myeloma Renal Failure: US Data Report on Kidney Transplant Outcomes.
42. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange
43. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis
44. Controlled Synthesis of Pure-Phase GaAs Nanowires through Shear Tension.
45. Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells.
46. CCL20 Is an Inducible Product of Human Airway Epithelia with Innate Immune Properties
47. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis
48. Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
49. Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD)
50. Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.